TY - JOUR
T1 - Prognostic role of EGR1 in breast cancer
T2 - A systematic review
AU - Saha, Subbroto Kumar
AU - Riazul Islam, S. M.
AU - Saha, Tripti
AU - Nishat, Afsana
AU - Biswas, Polash Kumar
AU - Gil, Minchan
AU - Nkenyereye, Lewis
AU - El-Sappagh, Shaker
AU - Islam, Md Saiful
AU - Cho, Ssang Goo
N1 - Funding Information:
This study was supported by grants from the National Research Foundation (NRF) funded by the Korean government (grant no. 2015R1A5A1009701 and 2019M3A9H1030682); and, in part by the National Research Foundation of Korea-Grant funded by the Korean Government (Ministry of Science and ICT)-NRF-2017R1A2B2012337. In addition, this paper was written as part of Konkuk University's research support program for its faculty on sabbatical leave in 2019-2020.
Publisher Copyright:
Copyright © 2021. by the The Korean Society for Biochemistry and Molecular Biology
PY - 2021/10/31
Y1 - 2021/10/31
N2 - EGR1 (early growth response 1) is dysregulated in many cancers and exhibits both tumor suppressor and promoter activities, making it an appealing target for cancer therapy. Here, we used a systematic multi-omics analysis to review the expression of EGR1 and its role in regulating clinical outcomes in breast cancer (BC). EGR1 expression, its promoter methylation, and protein expression pattern were assessed using various publicly available tools. COSMIC-based somatic mutations and cBioPortal-based copy number alterations were analyzed, and the prognostic roles of EGR1 in BC were determined using Prognoscan and Kaplan-Meier Plotter. We also used bc-GenEx-Miner to investigate the EGR1 co-expression profile. EGR1 was more often downregulated in BC tissues than in normal breast tissue, and its knockdown was positively correlated with poor survival. Low EGR1 expression levels were also associated with increased risk of ER+, PR+, and HER2-BCs. High positive correlations were observed among EGR1, DUSP1, FOS, FOSB, CYR61, and JUN mRNA expression in BC tissue. This systematic review suggested that EGR1 expression may serve as a prognostic marker for BC patients and that clinicopathological parameters influence its prognostic utility. In addition to EGR1, DUSP1, FOS, FOSB, CYR61, and JUN can jointly be considered prognostic indicators for BC. [BMB Reports 2021; 54(10): 497-504]
AB - EGR1 (early growth response 1) is dysregulated in many cancers and exhibits both tumor suppressor and promoter activities, making it an appealing target for cancer therapy. Here, we used a systematic multi-omics analysis to review the expression of EGR1 and its role in regulating clinical outcomes in breast cancer (BC). EGR1 expression, its promoter methylation, and protein expression pattern were assessed using various publicly available tools. COSMIC-based somatic mutations and cBioPortal-based copy number alterations were analyzed, and the prognostic roles of EGR1 in BC were determined using Prognoscan and Kaplan-Meier Plotter. We also used bc-GenEx-Miner to investigate the EGR1 co-expression profile. EGR1 was more often downregulated in BC tissues than in normal breast tissue, and its knockdown was positively correlated with poor survival. Low EGR1 expression levels were also associated with increased risk of ER+, PR+, and HER2-BCs. High positive correlations were observed among EGR1, DUSP1, FOS, FOSB, CYR61, and JUN mRNA expression in BC tissue. This systematic review suggested that EGR1 expression may serve as a prognostic marker for BC patients and that clinicopathological parameters influence its prognostic utility. In addition to EGR1, DUSP1, FOS, FOSB, CYR61, and JUN can jointly be considered prognostic indicators for BC. [BMB Reports 2021; 54(10): 497-504]
KW - Breast cancer
KW - Cancer progression
KW - EGR1
KW - Methylation
KW - Microarray
KW - Prognosis
KW - TCGA
KW - Tumor suppressor
UR - http://www.scopus.com/inward/record.url?scp=85121014031&partnerID=8YFLogxK
U2 - 10.5483/BMBRep.2021.54.10.087
DO - 10.5483/BMBRep.2021.54.10.087
M3 - Review article
C2 - 34488929
AN - SCOPUS:85121014031
VL - 54
SP - 497
EP - 504
JO - Journal of Biochemistry and Molecular Biology
JF - Journal of Biochemistry and Molecular Biology
SN - 1976-6696
IS - 10
ER -
